Affimed Therapeutics AG, a developer of bispecific antibody technology, has appointed Eugene Zhukovsky as chief scientific officer, effective 1 January 2012. He will replace Melvyn Little, who is retiring as CSO but will continue to work as a consultant to the company.
Dr Zhukovsky will join Affimed from Boehringer Ingelheim Pharmaceuticals Inc where he was a senior research fellow in the biotherapeutics department. He received his PhD in biochemistry from Brandeis University in the US.
Prof Little founded Affimed Therapeutics, a spin-out of the German Cancer Research Center in Heidelberg, in 2000. Affimed announced the appointment on 5 December.
Copyright 2011 Evernow Publishing Ltd